539 related articles for article (PubMed ID: 24244610)
1. The ratios of CD8+ T cells to CD4+CD25+ FOXP3+ and FOXP3- T cells correlate with poor clinical outcome in human serous ovarian cancer.
Preston CC; Maurer MJ; Oberg AL; Visscher DW; Kalli KR; Hartmann LC; Goode EL; Knutson KL
PLoS One; 2013; 8(11):e80063. PubMed ID: 24244610
[TBL] [Abstract][Full Text] [Related]
2. CD4+CD25+CD127-Foxp3+ and CD8+CD28- Tregs in Renal Transplant Recipients: Phenotypic Patterns, Association With Immunosuppressive Drugs, and Interaction With Effector CD8+ T Cells and CD19+IL-10+ Bregs.
Aly MG; Ibrahim EH; Karakizlis H; Weimer R; Opelz G; Morath C; Zeier M; Ekpoom N; Daniel V
Front Immunol; 2021; 12():716559. PubMed ID: 34335631
[TBL] [Abstract][Full Text] [Related]
3. Impact of the immune cell population in peripheral blood on response and survival in patients receiving neoadjuvant chemotherapy for advanced gastric cancer.
He Q; Li G; Ji X; Ma L; Wang X; Li Y; Fan C
Tumour Biol; 2017 May; 39(5):1010428317697571. PubMed ID: 28475005
[TBL] [Abstract][Full Text] [Related]
4. Increased regulatory T cells correlate with CD8 T-cell impairment and poor survival in hepatocellular carcinoma patients.
Fu J; Xu D; Liu Z; Shi M; Zhao P; Fu B; Zhang Z; Yang H; Zhang H; Zhou C; Yao J; Jin L; Wang H; Yang Y; Fu YX; Wang FS
Gastroenterology; 2007 Jun; 132(7):2328-39. PubMed ID: 17570208
[TBL] [Abstract][Full Text] [Related]
5. Analysis of CD8+ Treg cells in patients with ovarian cancer: a possible mechanism for immune impairment.
Zhang S; Ke X; Zeng S; Wu M; Lou J; Wu L; Huang P; Huang L; Wang F; Pan S
Cell Mol Immunol; 2015 Sep; 12(5):580-91. PubMed ID: 26166762
[TBL] [Abstract][Full Text] [Related]
6. Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer.
Sato E; Olson SH; Ahn J; Bundy B; Nishikawa H; Qian F; Jungbluth AA; Frosina D; Gnjatic S; Ambrosone C; Kepner J; Odunsi T; Ritter G; Lele S; Chen YT; Ohtani H; Old LJ; Odunsi K
Proc Natl Acad Sci U S A; 2005 Dec; 102(51):18538-43. PubMed ID: 16344461
[TBL] [Abstract][Full Text] [Related]
7. Providence of the CD25
Chakraborty S; Bhattacharjee P; Panda AK; Kajal K; Bose S; Sa G
Immunol Cell Biol; 2018 Nov; 96(10):1035-1048. PubMed ID: 29768737
[TBL] [Abstract][Full Text] [Related]
8. Increased frequency and FOXP3 expression of human CD8
Zahran AM; Nafady-Hego H; Mansor SG; Abbas WA; Abdel-Malek MO; Mekky MA; Hetta HF
Hum Immunol; 2019 Jul; 80(7):510-516. PubMed ID: 30904437
[TBL] [Abstract][Full Text] [Related]
9. Identification of CD8+CD25+Foxp3+ suppressive T cells in colorectal cancer tissue.
Chaput N; Louafi S; Bardier A; Charlotte F; Vaillant JC; Ménégaux F; Rosenzwajg M; Lemoine F; Klatzmann D; Taieb J
Gut; 2009 Apr; 58(4):520-9. PubMed ID: 19022917
[TBL] [Abstract][Full Text] [Related]
10. Decrease of CD4(+) CD25(+) CD127(low) FoxP3(+) regulatory T cells with impaired suppressive function in untreated ulcerative colitis patients.
Mohammadnia-Afrouzi M; Zavaran Hosseini A; Khalili A; Abediankenari S; Hosseini V; Maleki I
Autoimmunity; 2015; 48(8):556-61. PubMed ID: 26333292
[TBL] [Abstract][Full Text] [Related]
11. Aberrant peripheral blood CD4
Dehghani M; Kalani M; Golmoghaddam H; Ramzi M; Arandi N
Cancer Immunol Immunother; 2020 Sep; 69(9):1917-1928. PubMed ID: 32385519
[TBL] [Abstract][Full Text] [Related]
12. Increase in tumour-infiltrating lymphocytes with regulatory T cell immunophenotypes and reduced zeta-chain expression in nasopharyngeal carcinoma patients.
Yip WK; Abdullah MA; Yusoff SM; Seow HF
Clin Exp Immunol; 2009 Mar; 155(3):412-22. PubMed ID: 19220831
[TBL] [Abstract][Full Text] [Related]
13. NY-ESO-1-specific circulating CD4+ T cells in ovarian cancer patients are prevalently T(H)1 type cells undetectable in the CD25+ FOXP3+ Treg compartment.
Redjimi N; Duperrier-Amouriaux K; Raimbaud I; Luescher I; Dojcinovic D; Classe JM; Berton-Rigaud D; Frenel JS; Bourbouloux E; Valmori D; Ayyoub M
PLoS One; 2011; 6(7):e22845. PubMed ID: 21829534
[TBL] [Abstract][Full Text] [Related]
14. Intense Foxp3+ CD25+ regulatory T-cell infiltration is associated with high-grade cutaneous squamous cell carcinoma and counterbalanced by CD8+/Foxp3+ CD25+ ratio.
Azzimonti B; Zavattaro E; Provasi M; Vidali M; Conca A; Catalano E; Rimondini L; Colombo E; Valente G
Br J Dermatol; 2015 Jan; 172(1):64-73. PubMed ID: 24910265
[TBL] [Abstract][Full Text] [Related]
15. Regulatory T cells express Tumor Necrosis Factor Receptor 2 with the highest intensity among CD4
Ghods A; Mehdipour F; Shariat M; Talei AR; Ghaderi A
Mol Immunol; 2021 Sep; 137():52-56. PubMed ID: 34214829
[TBL] [Abstract][Full Text] [Related]
16. The expression of the regulatory T cell-specific forkhead box transcription factor FoxP3 is associated with poor prognosis in ovarian cancer.
Wolf D; Wolf AM; Rumpold H; Fiegl H; Zeimet AG; Muller-Holzner E; Deibl M; Gastl G; Gunsilius E; Marth C
Clin Cancer Res; 2005 Dec; 11(23):8326-31. PubMed ID: 16322292
[TBL] [Abstract][Full Text] [Related]
17. CD25 identifies a subset of CD4⁺FoxP3⁻ TIL that are exhausted yet prognostically favorable in human ovarian cancer.
deLeeuw RJ; Kroeger DR; Kost SE; Chang PP; Webb JR; Nelson BH
Cancer Immunol Res; 2015 Mar; 3(3):245-53. PubMed ID: 25480168
[TBL] [Abstract][Full Text] [Related]
18. A reversed CD4/CD8 ratio of tumor-infiltrating lymphocytes and a high percentage of CD4(+)FOXP3(+) regulatory T cells are significantly associated with clinical outcome in squamous cell carcinoma of the cervix.
Shah W; Yan X; Jing L; Zhou Y; Chen H; Wang Y
Cell Mol Immunol; 2011 Jan; 8(1):59-66. PubMed ID: 21200385
[TBL] [Abstract][Full Text] [Related]
19. Serum CD95L Level Correlates with Tumor Immune Infiltration and Is a Positive Prognostic Marker for Advanced High-Grade Serous Ovarian Cancer.
De La Motte Rouge T; Corné J; Cauchois A; Le Boulch M; Poupon C; Henno S; Rioux-Leclercq N; Le Pabic E; Laviolle B; Catros V; Levêque J; Fautrel A; Le Gallo M; Legembre P; Lavoué V
Mol Cancer Res; 2019 Dec; 17(12):2537-2548. PubMed ID: 31537619
[TBL] [Abstract][Full Text] [Related]
20. CD8+ Foxp3+ regulatory T cells mediate immunosuppression in prostate cancer.
Kiniwa Y; Miyahara Y; Wang HY; Peng W; Peng G; Wheeler TM; Thompson TC; Old LJ; Wang RF
Clin Cancer Res; 2007 Dec; 13(23):6947-58. PubMed ID: 18056169
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
